CDT Equity Inc(CDT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -141725.05 | Insider Own | - | Shs Outstand | 1.1M | Perf Week | -39.71% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.5M | Perf Month | -95.93% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 0.06% | Short Float | 7.49% | Perf Quarter | -99.82% |
| Income | -0.04B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.05 | Perf Half Y | -99.98% |
| Sales | 0.00B | P/B | 0 | EPS next 5Y | - | ROA | -55.16% | Short Interest | 0.04M | Perf YTD | -100% |
| Book/sh | 4083.99 | P/C | 0.22 | EPS past 3/5Y | 61.18% -99.07% | ROE | -69.68% | 52W High | -100% ($20312.50) | Perf Year | -100% |
| Cash/sh | 0.66 | P/FCF | - | Sales past 3/5Y | - | ROIC | -36.03% | 52W Low | -0.28% ($0.15) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 98.24% | Gross Margin | - | Volatility(W/M) | 21.24% 18.49% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.29 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.13 | EPS Q/Q | 99.92% | Profit Margin | - | RSI (14) | 15.19 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.13 | Sales Q/Q | - | SMA20 | -84.32% ($0.89) | Beta | 1.57 | Target Price | - |
| Payout | - | Debt/Eq | 0.01 | Earnings | - | SMA50 | -99.32% ($20.59) | Rel Volume | 2.09 | Prev Close | $0.16 |
| Employees | 4 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -99.99% ($1400) | Avg Volume(3M) | 0.82M | Price | $0.14 |
| IPO | 2022/3/28 | Option/Short | No/Yes | Trades | 1341 | Volume | 1,721,495 | Change | -8.99% |
🧪 CDT Equity () is a biopharmaceutical company specializing in AI-driven drug repurposing and capital-efficient asset development, formerly known as Conduit Pharmaceuticals. Its core assets are glucokinase activator candidates — AZD1656, AZD5658, and AZD5904 — in-licensed from AstraZeneca. The company is advancing Phase II clinical trials focused on autoimmune diseases (such as lupus and ANCA-associated vasculitis) while pursuing expansion through partnerships.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded more than usual. That is 209% of its average volume.
CDT has weak earnings and a weak balance sheet
Review management risk carefully before investing
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -100.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.1%.
Tap to view numbers
It ranks #595 of 595 in the industry
Based on market cap of $0M.
FAQ
What kind of company is CDT?
CDT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CDT?
The market cap of CDT is approximately $0M, ranking 5,894 within its sector.
What is the 52-week high and low for CDT?
CDT has recorded a 52-week high of $20312.50 and a low of $0.15.
